FDA Inspection 1228973 — Celgene Corporation
The FDA completed an inspection of Celgene Corporation on Jan 31, 2024 in Summit, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jan 31, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Summit, NJ (United States)
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)